Loyal, a biotech firm based in San Francisco, is on the verge of gaining FDA approval for their drug, LOY-001. This medication is specifically tailored for large-breed dogs weighing 40 pounds or more. It operates by engaging with the hormone IGF-1, effectively slowing down aging mechanisms and proactively preventing diseases before they manifest symptoms.

The objective of Loyal is to fill a crucial void, given the absence of FDA-sanctioned drugs serving this purpose. CEO Celine Halioua stresses the substantial impact this could have on the 25 million large-breed dogs across the United States.